GCAP-II: isolation and characterization of the circulating form of human uroguanylin

R Hess, M Kuhn, P Schulz-Knappe, M Raida, M Fuchs… - FEBS letters, 1995 - Elsevier
R Hess, M Kuhn, P Schulz-Knappe, M Raida, M Fuchs, J Klodt, K Adermann, V Kaever…
FEBS letters, 1995Elsevier
The systematic isolation of circulating regulatory peptides which generate cGMP as second
messenger resulted in the identification of a novel member of the guanylin family. In the
present study we describe the purification and amino acid sequence of a new guanylate
cyclase C activating peptide (GCAP-II). GCAP-II contains 24 amino acids in the following
sequence: FKTLRTIANDDCELCVNVACTGCL. Its molecular mass is 2597.7 Da. The 16 C-
terminal amino acids are identical to uroguanylin from human urine. Native and synthetic …
The systematic isolation of circulating regulatory peptides which generate cGMP as second messenger resulted in the identification of a novel member of the guanylin family. In the present study we describe the purification and amino acid sequence of a new guanylate cyclase C activating peptide (GCAP-II). GCAP-II contains 24 amino acids in the following sequence: FKTLRTIANDDCELCVNVACTGCL. Its molecular mass is 2597.7 Da. The 16 C-terminal amino acids are identical to uroguanylin from human urine. Native and synthetic GCAP-II activate GC-C, the specific guanylate cyclase receptor, of cultured human colon carcinoma (T84) cells. GCAP-II stimulates chloride secretion in isolated human intestinal mucosa mediated by intracellular cGMP increase. GCAP-II specific antibodies were used to localize the peptide by immunohistochemistry in entero-endocrine cells of the colonic mucosa.
Elsevier